Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Labopin, Myriam  [Clear All Filters]
Journal Article
Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AMaria, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.
Duléry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, Calabro M, Van de Wyngaert Z, Bonnin A, Ledraa T, et al. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplant. 2023.
Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de la Tour RPeffault, Vigouroux S, et al. Results from a clofarabine-busulfan containing reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase II prospective CLORIC trial. Haematologica. 2014.
Shouval R, Labopin M, Bomze D, Baerlocher GM, Capria S, Blaise D, Hänel M, Forcade E, Huynh A, Saccardi R, et al. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplant. 2020.
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G-N, Blau IWolfgang, Salmenniemi U, Socié G, et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant. 2023.
Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.
Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019.
Velázquez GFilippini, Labopin M, Tischer J, Raiola AMaria, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois C-E, Kröger N, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.
Le Bourgeois A, Labopin M, Marçais A, de Latour RPeffault, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of th. Hemasphere. 2023;7(7):e920.
Belkacemi Y, Labopin M, Giebel S, Gorin NClaude, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPm, Cornelissen JJ, et al. Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. Int J Radiat Oncol Biol Phys. 2018.
Gorin N-C, Labopin M, Blaise D, de Groot M, Socié G, Bourhis JHenri, Ciceri F, Polge E, Nagler A, Mohty M. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood a. Cancer. 2019.
Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji R-M, Casper J, Edinger M, Žák P, Yakoub-Agha I, Ciceri F, et al. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute . Bone Marrow Transplant. 2023.
Battipaglia G, Labopin M, Mielke S, Ruggeri A, Ozkurt ZNur, Bourhis JHenri, Rabitsch W, Yakoub-Agha I, Grillo G, Sanz J, et al. Thiotepa-based regimens are a valid alternative to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT. Transplant Cell Ther. 2023.
Saraceni F, Labopin M, Raiola AM, Blaise D, Reményi P, Sorà F, Pavlu J, Bramanti S, Busca A, Berceanu A, et al. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7(10):e952.
Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JLuiz, Bruno B, Castagna L, Moiseev ISergeevich, Vitek A, et al. The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji R-M, Potter V, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par. Bone Marrow Transplant. 2022.
Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JHenri, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R-M, Niederwieser D, Volin L, Markiewicz M, Arnold R, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysis. J Intern Med. 2018.
Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014.
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9(1):89.
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EMaria, Versluis J, Schroeder T, Blau IWolfgang, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Remenyi PPal, Versluis J, Rovira M, Blaise D, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT. Blood. 2024.

Pages